Refine
Has Fulltext
- yes (58)
Is part of the Bibliography
- yes (58)
Year of publication
Document Type
- Journal article (56)
- Doctoral Thesis (1)
- Report (1)
Keywords
- CML (2)
- Neisseria gonorrhoeae (2)
- Translational research (2)
- cancer (2)
- deadwood enrichment (2)
- gene regulation (2)
- management (2)
- next generation sequencing (2)
- reactive electrophilic species (2)
- remote sensing (2)
- salt stress (2)
- saproxylic beetles (2)
- survival (2)
- (classical and atypical) Werner syndrome (1)
- 12-oxo-phytodienoic acid (1)
- ABCG2 (1)
- ABL gene (1)
- ADHD (1)
- Abstimmbare Laser (1)
- Agent (1)
- Aging (1)
- Alpha therapy (1)
- Alzheimer's disease (1)
- Arthropod (1)
- Autoimmune diseases (1)
- B cell malignancies (1)
- B cells (1)
- BCOR (1)
- BCORL1 (1)
- BCR‐ABL (1)
- BETA-Diversität (1)
- BETA-Multifunktionalität (1)
- BRAF(V600E) mutation (1)
- Biodiversität (1)
- Biologie (1)
- Biomarker (1)
- Bone marrow transplantantation (1)
- Breast-tumors (1)
- COVID-19 (1)
- COX-2 (1)
- CXCR4 (1)
- Cancer (1)
- Cancer genetics (1)
- Cardiovascular risk factors (1)
- Cardiovascular risk prediction (1)
- Carotid intima-media thickness (CIMT) (1)
- Carotid segment (1)
- Carotid ultrasound (1)
- Chronic myeloid leukaemia (1)
- Cognitive control (1)
- DFB-Laser (1)
- EZH1 (1)
- EZH2 (1)
- EZH2 differentiation trichostatin (1)
- Exercise (1)
- Expression (1)
- Factor receptor (1)
- Forschungsstation Fabrikschleichach (1)
- GRAID (1)
- Graft-versus-leukemia (1)
- H3K27me3 (1)
- HLA-E matching (1)
- HSTC outcome (1)
- HUWE1 (1)
- Halbleiterlaser (1)
- Hippocampus (1)
- Human Physiome (1)
- Imatinib (1)
- Immunologie (1)
- In-vivo (1)
- Inhibitor (1)
- LASP1 (1)
- LND (1)
- LNE (1)
- Laserarray (1)
- Lymantria dispar (1)
- M1/M2 macrophages (1)
- MFM (1)
- MIZ1 (1)
- MYC (1)
- Medical research (1)
- Molecularly targeted therapy (1)
- N170 (1)
- NFATc1 (1)
- NHX1 (1)
- NaCl transport (1)
- Neurotrophic factors (1)
- Nude-mice (1)
- Organische Chemie (1)
- P100 (1)
- PTCL (1)
- Pou2af1 (1)
- Prediction (1)
- Regulatory-cells (1)
- Rheumatoid arthritis (1)
- Risk factors (1)
- Salt Overly Sensitive pathway (1)
- Selective attention (1)
- Sentinel-1 (1)
- Staphylococcus aureus (1)
- Suppression (1)
- T cell differentiation (1)
- T cells (1)
- T-cell non-Hodgkin's lymphomas (1)
- TH1-induced senescence (1)
- TH17 cells (1)
- Tissue (1)
- Tumor-necrosis-factor (1)
- VAL66MET polymorphism (1)
- Vascular plasticity (1)
- Waldökosystem (1)
- Working memory (1)
- abscisic acid (ABA) (1)
- accessibility (1)
- acquired thermotolerance (1)
- acquisition (1)
- activation (1)
- acute leukemia (AL) (1)
- acute myeloid leukemia (1)
- adhesion dynamics (1)
- adolescents (1)
- adrenal cancer (1)
- adrenocortical carcinoma (1)
- amino acid transporter (1)
- anaemia (1)
- aneurysmal subarachnoid haemorrhage (1)
- antibodies (1)
- apolipoprotein-E4 (1)
- arabidopsis-thaliana (1)
- arterial stiffening (1)
- assembly mechanisms (1)
- association (1)
- atherosclerosis (1)
- autotoxicity (1)
- bcl-2 associated athanogene protein 3 (1)
- beech forest (1)
- beetle (1)
- beta diversity (1)
- beta-multifunctionality (1)
- biodiversity (1)
- bipartite metabolism (1)
- bipolar disorder (1)
- bird communities (1)
- bisulfite pyrosequencing (1)
- body size (1)
- bohemian forest ecosystem (1)
- brain (1)
- brain computer interface (1)
- breakpoint (1)
- breast cancer (1)
- broadleaf tree species (1)
- calcification (1)
- calcium signaling (1)
- cancer-targeted IL-12 (1)
- canopy herbivory (1)
- carotid artery disease (1)
- cell death (1)
- children (1)
- chronic myelogenous leukemia (1)
- chronic myeloid leukemia (1)
- chronic phase (1)
- coatings (1)
- colorectal cancer (1)
- community‐weighted mean (1)
- conservation (1)
- containment (1)
- crowded housing (1)
- cytogenetic response (1)
- cytosolic pH (1)
- cytotoxic T cells (1)
- cytotoxicity (1)
- data pool (1)
- dead-wood enrichment (1)
- deadwood (1)
- defoliation severity (1)
- detoxification (1)
- dfb-laser (1)
- different imatinib dose regimens (1)
- differentiation (1)
- digestive system (1)
- disability (1)
- dispersal ability (1)
- dissection (1)
- distant metastases (1)
- diversity (1)
- drug discovery (1)
- early applied higher imatinib dosages (1)
- early respiratory-failure (1)
- elderly (1)
- environmental filtering (1)
- enzyme-linked immunoassays (1)
- epigenetics (1)
- epigenomic landscapes (1)
- epithelial cells (1)
- evidence‐based medicine (1)
- ex vivo expansion (1)
- extinction risk (1)
- fear conditioning (1)
- fire (1)
- focal adhesions (1)
- follicular T helper cells (1)
- force (1)
- forest (1)
- forest biodiversity (1)
- forest conservation (1)
- forest ecosystem science (1)
- forest management (1)
- forest physiognomy (1)
- forestry (1)
- functional traits (1)
- gene-expression (1)
- genome-wide association (1)
- geographic information science (1)
- germinal center (1)
- glycophyte Arabidopsis (1)
- guard cell (1)
- guidelines (1)
- gypsy moth (1)
- habitat heterogeneity (1)
- halophyte Thellungiella/Eutrema (1)
- health care service research (1)
- hearing impairment (1)
- heart (1)
- heart failure (1)
- heat shock response (1)
- heat stress (1)
- hematopoietic stem cell transplantation (HSCT) (1)
- host cells (1)
- human leukocyte antigen-E (HLA-E) (1)
- humanized mice (1)
- humoral immunity (1)
- hybrid messenger RNA (1)
- immune cells (1)
- immunocytokine (1)
- immunohistochemistry (1)
- immunotherapy (1)
- impact (1)
- in vivo polycomb (1)
- independence (1)
- insect decline (1)
- insect disturbance (1)
- integrative management strategy (1)
- intra-annual time-series (1)
- intracerebral haemorrhage (1)
- ion transport (1)
- isothiocyanates (1)
- jasmonates (1)
- kidneys (1)
- land sharing (1)
- land use (1)
- laser array (1)
- leaf response (1)
- learning (1)
- limited mobility (1)
- loss-of-function (1)
- lowland beech forests (1)
- lymph node dissection (1)
- lymphadenectomy (1)
- lymphocyte activation (1)
- machine learning (1)
- macrophages (1)
- major depressive disorder (1)
- managing big data (1)
- medial prefrontal cortex (mPFC) (1)
- medicine (1)
- memory B cells (1)
- memory consolidation and extinction (1)
- messenger RNA (1)
- meta-analysis (1)
- methylation array (1)
- migrants (1)
- migration (1)
- model (1)
- molecular subtypes (1)
- mood disorder (1)
- morphometry (1)
- muscular-dystrophy (1)
- mustard oil bomb (1)
- myopathy (1)
- natural disturbance (1)
- near-infrared spectroscopy (1)
- networks (1)
- neurotrophic factor gene (1)
- neutral processes (1)
- neutrophils (1)
- nilotinib (1)
- no correlation (1)
- older patients (1)
- osmotic effects (1)
- papillary (1)
- patient blood management (1)
- pediatric adrenocortical adenoma (1)
- pediatric adrenocortical cancer (1)
- pediatric adrenocortical tumor (1)
- pharmacology (1)
- phytoprostanes (1)
- plant composition (1)
- plants (1)
- polymerase-chain-reaktion (1)
- polyneuropathy (1)
- posttranscriptional regulation (1)
- precursor cells (1)
- premature aging (1)
- prognostic factors (1)
- protein aggregation (1)
- psychiatry (1)
- radioiodine therapy (1)
- red blood cell transfusion (1)
- red lists (1)
- redox homeostasis (1)
- refugees (1)
- regional species pool (1)
- remote sensing‐enabled essential biodiversity variables (1)
- repositories (1)
- reproducible science (1)
- respiratory infection (1)
- restoration strategy (1)
- review (1)
- rhabdomyosarcoma (1)
- risk stratification (1)
- sRNA (1)
- saproxylic organisms (1)
- saproxylic species (1)
- seasonality (1)
- segmental progeria (1)
- semiconductor lasers (1)
- sequence variations (1)
- service infrastructure (1)
- shock response (1)
- signal transduction (1)
- skeletal myopathy (1)
- soil (1)
- species traits (1)
- species turnover (1)
- spiders (1)
- standards (1)
- stomata (1)
- stress (1)
- sulforaphane (1)
- sun exposure (1)
- surgery (1)
- tension (1)
- therapy (1)
- thermotolerance (1)
- time series (1)
- tissue morphogenesis (1)
- traction (1)
- transcranial magnetic stimulation (TMS) (1)
- transcription deficiency (1)
- transcripts (1)
- transplantation states genes (1)
- transposable elements (1)
- treatment response (1)
- trophic position (1)
- tumor heterogeneity (1)
- tumor-infiltrating lymphocytes (1)
- tunable laser (1)
- ubiquitination (1)
- unfolded protein response (1)
- verbal fluency task (1)
- windthrow (1)
- wood‐inhabiting fungi (1)
- β-diversity (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (20)
- Medizinische Klinik und Poliklinik II (9)
- Pathologisches Institut (7)
- Julius-von-Sachs-Institut für Biowissenschaften (6)
- Medizinische Klinik und Poliklinik I (5)
- Institut für Humangenetik (4)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (4)
- Institut für Geographie und Geologie (3)
- Institut für Klinische Epidemiologie und Biometrie (3)
- Institut für Molekulare Infektionsbiologie (3)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 229289 (1)
- 288566 (1)
- 834709 (1)
- ZAM 5-85018031 (1)
The expression of T-cell-associated serine proteinase 1 (MTSP-1) in vivo during Leishmania major infection was analyzed in genetically resistant C57BL/6 mice and in genetically susceptible BALB/c mice. Using a monoclonal antibody as well as an RNA probe specific for MTSP-1 to stain tissue sections, we found T cells expressing MTSP-1 in skin lesions and spleens of mice of both strains. In skin lesions, MTSP-1-positive T cells could be detected as early as 3 days after infection. Most importantly, the frequency of T cells expressing MTSP-1 was significantly higher in susceptible BALB/c mice than in resistant C57BL/6 mice. These findings suggest that MTSP-1 is associated with disease-promoting T cells and that it may be an effector molecule involved in the pathogenesis of cutaneous leishmaniasis.
No abstract available
Abstimmbare Halbleiterlaser und schmalbandige Laserarrays mit verteilter lateraler Rückkopplung
(2003)
Im Rahmen dieser Arbeit wurden zwei verschiedene Typen von Halbleiterlasern mit verteilter Rückkopplung (DFB-Laser) entwickelt. Die Laser basieren auf Rippenwellenleitern und verfügen zusätzlich über ein dazu senkrecht orientiertes Metallgitter. Der evaneszente Teil der im Rippenwellenleiter geführten Lichtwelle überlappt mit dem Gitter. Durch diese periodische Variation des effektiven Brechungsindex wird die verteilte Rückkopplung gewährleistet, was eine longitudinal monomodige Laseremission zur Folge hat. Beiden Lasertypen ist gemeinsam, dass der Herstellungsprozess auf einem vom Materialsystem unabhängigen Konzept basiert. Diese Tatsache ist von besonderem Interesse, da so entsprechende Laser für unterschiedlichste Wellenlängenbereiche gefertigt werden können, ohne hierfür neue Herstellungsverfahren zu entwickeln. Den ersten Schwerpunkt der Arbeit bilden Untersuchungen zu sog. abstimmbaren Lasern, deren Emissionswellenlänge innerhalb eines relativ großen Bereichs quasikontinuierlich einstellbar ist. Der Abstimmmechanismus kann mit dem Vernier-Prinzip erklärt werden. Der Laser besteht hierbei aus zwei gekoppelten Segmenten, die jeweils über eine Reihe von Moden (Modenkamm) verfügen. Der Abstand der Moden innerhalb eines Segments ist konstant, wohingegen die Modenabstände der beiden Segmente leicht unterschiedlich sind. Die Emissionswellenlänge des Lasers ist bestimmt durch den Überlapp zweier Moden aus den beiden Segmenten, wobei die Modenkämme so ausgelegt sind, dass gleichzeitig maximal ein Modenpaar überlappt. Eine kleine relative Verschiebung der beiden Modenkämme führt zu einer vergleichsweise großen Verschiebung der Emissionswellenlänge auf Grund des veränderten Überlapps. Die Modenkämme wurden durch spezielle DFB-Gitter, sog. binary superimposed gratings (BSG), realisiert, die, anders als bei konventionellen DFB-Lasern, für mehrere Bragg-Wellenlängen konstruktive Interferenz zulassen und erstmalig bei DFB-Lasern eingesetzt wurden. BSGs zeichnen sich durch sehr gute optische Eigenschaften bei gleichzeitig einfacher Herstellung aus. Zum Abstimmen der Wellenlänge wurde der Brechungsindex des Lasers gezielt durch den Injektionsstrom bzw. die Bauteiltemperatur verändert. Im Rahmen dieser Arbeit konnten abstimmbare Laser auf unterschiedlichen Materialsystemen (InGaAs/GaAs, GaInNAs/GaAs, InGaAsP/InP) hergestellt werden. Der maximale diskrete Abstimmbereich beträgt 38 nm bzw. 8,9 THz und ist durch die Breite des Verstärkungsspektrums limitiert. Quasikontinuierlich konnte ein Abstimmbereich von 15 nm bzw. 3,9 THz erreicht werden. Die typische minimale Seitenmodenunterdrückung (SMSR) beträgt 30 bis 35 dB. Durch Hinzufügen eines dritten Segments ohne Gitter konnte die Ausgangsleistung unabhängig von der Wellenlänge konstant gehalten werden. Den zweiten Schwerpunkt der Arbeit bildet die Entwicklung von DFB-Laser-Arrays mit dem Ziel, longitudinal monomodige Laser mit hoher Ausgangsleistung zu erhalten. Die DFB-Laser-Arrays basieren auf dem oben beschriebenen Prinzip von DFB-Lasern mit lateralem Metallgitter und verfügen über mehrere Rippenwellenleiter, die im lateralen Abstand von wenigen Mikrometern angeordnet sind. Für große Abstände zwischen den einzelnen Lasern des Arrays (Elemente) emittieren diese, weitgehend unabhängig von einander, jeweils longitudinal monomodiges Licht (quasimonochromatische Emission). Die spektrale Breite beträgt hierbei typischerweise 50 bis 70 GHz. Für kleine Elementabstände koppeln die einzelnen Lichtwellen miteinander, was zu einer mit einem konventionellen DFB-Laser vergleichbaren Linienbreite führt. Während die ungekoppelten Arrays über ein gaußförmiges Fernfeld verfügen, ergibt sich für die gekoppelten Arrays ein Interferenzmuster, das stark von verschiedenen Laserparametern (wie z. B. dem Elementabstand) abhängt. Bei InGaAs/GaAs basierenden Arrays (Wellenlänge ca. 980 nm) ergibt sich für DFB-Laser-Arrays mit vier Elementen eine Ausgangsleistung von ca. 200 mW pro Facette, die durch die Wärmeabfuhr begrenzt wird. Trotz der starken thermischen Limitierung (die Laser waren nicht aufgebaut) konnte die 3,5-fache Ausgangsleistung eines Referenzlasers erzielt werden. Bei InGaSb/GaSb basierenden Arrays mit vier Elementen (Wellenlänge ca. 2,0 µm) konnte eine Ausgangsleistung von ca. 30 mW pro Facette erreicht werden, was dem 3,3-fachen eines Referenzlasers entspricht. Die Verwendung von DFB-Laser-Arrays führt folglich zu einer signifikanten Leistungssteigerung, die sich durch geeignete Maßnahmen (Facettenvergütung, Montage, Skalierung) noch weiter erhöhen ließe.
Introduction:
Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin’s lymphoma in a real-life clinical setting.
Methods:
Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
Results:
A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician’s visual analogue scale; mean improvement from baseline of 12.1 mm)
Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy. In this study, we analyzed for the first time the therapeutic efficacy of the oncolytic vaccinia virus GLV-1h68 in two human hepatocellular carcinoma cell lines HuH7 and PLC/PRF/5 (PLC) in cell culture and in tumor xenograft models. By viral proliferation assays and cell survival tests, we demonstrated that GLV-1h68 efficiently colonized, replicated in, and did lyse these cancer cells in culture. Experiments with HuH7 and PLC xenografts have revealed that a single intravenous injection (i.v.) of mice with GLV-1h68 resulted in a significant reduction of primary tumor sizes compared to uninjected controls. In addition, replication of GLV-1h68 in tumor cells led to strong inflammatory and oncolytic effects resulting in intense infiltration of MHC class II-positive cells like neutrophils, macrophages, B cells and dendritic cells and in up-regulation of 13 pro-inflammatory cytokines. Furthermore, GLV-1h68 infection of PLC tumors inhibited the formation of hemorrhagic structures which occur naturally in PLC tumors. Interestingly, we found a strongly reduced vascular density in infected PLC tumors only, but not in the non-hemorrhagic HuH7 tumor model. These data demonstrate that the GLV-1h68 vaccinia virus may have an enormous potential for treatment of human hepatocellular carcinoma in man.
Background: Data from clinical studies and results from animal models suggest an involvement of the neurotrophin system in the pathology of depression and antidepressant treatment response. Genetic variations within the genes coding for the brain-derived neurotrophic factor (BDNF) and its key receptor Trkb (NTRK2) may therefore influence the response to antidepressant treatment.
Methods: We performed a single and multi-marker association study with antidepressant treatment outcome in 398 depressed Caucasian inpatients participating in the Munich Antidepressant Response Signature (MARS) project. Two Caucasian replication samples (N = 249 and N = 247) were investigated, resulting in a total number of 894 patients. 18 tagging SNPs in the BDNF gene region and 64 tagging SNPs in the NTRK2 gene region were genotyped in the discovery sample; 16 nominally associated SNPs were tested in two replication samples.
Results: In the discovery analysis, 7 BDNF SNPs and 9 NTRK2 SNPs were nominally associated with treatment response. Three NTRK2 SNPs (rs10868223, rs1659412 and rs11140778) also showed associations in at least one replication sample and in the combined sample with the same direction of effects (\(P_{corr}\) = .018, \(P_{corr}\) = .015 and \(P_{corr}\) = .004, respectively). We observed an across-gene BDNF-NTRK2 SNP interaction for rs4923468 and rs1387926. No robust interaction of associated SNPs was found in an analysis of BDNF serum protein levels as a predictor for treatment outcome in a subset of 93 patients.
Conclusions/Limitations: Although not all associations in the discovery analysis could be unambiguously replicated, the findings of the present study identified single nucleotide variations in the BDNF and NTRK2 genes that might be involved in antidepressant treatment outcome and that have not been previously reported in this context. These new variants need further validation in future association studies.
Background
The impact of task relevance on event-related potential amplitudes of early visual processing was previously demonstrated. Study designs, however, differ greatly, not allowing simultaneous investigation of how both degree of distraction and task relevance influence processing variations. In our study, we combined different features of previous tasks. We used a modified 1-back task in which task relevant and task irrelevant stimuli were alternately presented. The task irrelevant stimuli could be from the same or from a different category as the task relevant stimuli, thereby producing high and low distracting task irrelevant stimuli. In addition, the paradigm comprised a passive viewing condition. Thus, our paradigm enabled us to compare the processing of task relevant stimuli, task irrelevant stimuli with differing degrees of distraction, and passively viewed stimuli. EEG data from twenty participants was collected and mean P100 and N170 amplitudes were analyzed. Furthermore, a potential connection of stimulus processing and symptoms of attention deficit hyperactivity disorder (ADHD) was investigated.
Results
Our results show a modulation of peak N170 amplitudes by task relevance. N170 amplitudes to task relevant stimuli were significantly higher than to high distracting task irrelevant or passively viewed stimuli. In addition, amplitudes to low distracting task irrelevant stimuli were significantly higher than to high distracting stimuli. N170 amplitudes to passively viewed stimuli were not significantly different from either kind of task irrelevant stimuli. Participants with more symptoms of hyperactivity and impulsivity showed decreased N170 amplitudes across all task conditions. On a behavioral level, lower N170 enhancement efficiency was significantly correlated with false alarm responses.
Conclusions
Our results point to a processing enhancement of task relevant stimuli. Unlike P100 amplitudes, N170 amplitudes were strongly influenced by enhancement and enhancement efficiency seemed to have direct behavioral consequences. These findings have potential implications for models of clinical disorders affecting selective attention, especially ADHD.
The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study in newly diagnosed BCR-ABL-positive chronic myeloid leukemia in chronic phase. Patients randomized to imatinib 400 mg/day (IM400) or imatinib 800 mg/day (IM800) and stratified according to age (≥65 years vs. <65 years) were compared regarding dose, response, adverse events, rates of progression, and survival. The full 800 mg dose was given after a 6-week run-in period with imatinib 400 mg/day. The dose could then be reduced according to tolerability. A total of 828 patients were randomized to IM400 or IM800. Seven hundred eighty-four patients were evaluable (IM400, 382; IM800, 402). One hundred ten patients (29 %) on IM400 and 83 (21 %) on IM800 were ≥65 years. The median dose per day was lower for patients ≥65 years on IM800, with the highest median dose in the first year (466 mg/day for patients ≥65 years vs. 630 mg/day for patients <65 years). Older patients on IM800 achieved major molecular remission and deep molecular remission as fast as younger patients, in contrast to standard dose imatinib with which older patients achieved remissions much later than younger patients. Grades 3 and 4 adverse events were similar in both age groups. Five-year relative survival for older patients was comparable to that of younger patients. We suggest that the optimal dose for older patients is higher than 400 mg/day. ClinicalTrials.gov identifier: NCT00055874
Background: Myofibrillar myopathies (MFM) are a group of phenotypically and genetically heterogeneous neuromuscular disorders, which are characterized by protein aggregations in muscle fibres and can be associated with multisystemic involvement.
Methods: We screened a large cohort of 38 index patients with MFM for mutations in the nine thus far known causative genes using Sanger and next generation sequencing (NGS). We studied the clinical and histopathological characteristics in 38 index patients and five additional relatives (n = 43) and particularly focused on the associated multisystemic symptoms.
Results: We identified 14 heterozygous mutations (diagnostic yield of 37%), among them the novel p. Pro209Gln mutation in the BAG3 gene, which was associated with onset in adulthood, a mild phenotype and an axonal sensorimotor polyneuropathy, in the absence of giant axons at the nerve biopsy. We revealed several novel clinical phenotypes and unusual multisystemic presentations with previously described mutations: hearing impairment with a FLNC mutation, dysphonia with a mutation in DES and the first patient with a FLNC mutation presenting respiratory insufficiency as the initial symptom. Moreover, we described for the first time respiratory insufficiency occurring in a patient with the p. Gly154Ser mutation in CRYAB. Interestingly, we detected a polyneuropathy in 28% of the MFM patients, including a BAG3 and a MYOT case, and hearing impairment in 13%, including one patient with a FLNC mutation and two with mutations in the DES gene. In four index patients with a mutation in one of the MFM genes, typical histological findings were only identified at the ultrastructural level (29%).
Conclusions: We conclude that extraskeletal symptoms frequently occur in MFM, particularly cardiac and respiratory involvement, polyneuropathy and/or deafness. BAG3 mutations should be considered even in cases with a mild phenotype or an adult onset. We identified a genetic defect in one of the known genes in less than half of the MFM patients, indicating that more causative genes are still to be found. Next generation sequencing techniques should be helpful in achieving this aim.